Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
We offer a one-stop platform for comprehensive breast cancer drug development, tumor model construction, and basic research services, empowering researchers to accelerate breakthrough therapeutic discoveries.
Get a Quote
Breast cancer is characterized by the presence of malignant tumors in breast tissue. Its development is influenced by various factors, including genetic mutations, hormone levels, family medical history, and lifestyle choices. Breast cancer can originate in the lobules, which are glands responsible for milk production, or in the ducts, which are the channels that transport milk to the nipples.
Current treatment options for breast cancer encompass surgery, radiotherapy, chemotherapy, endocrine therapy, and targeted therapy. In the realm of drug research, targeted therapies such as Herceptin (trastuzumab) and endocrine therapies like Tamoxifen have been effectively utilized in breast cancer treatment. In recent years, researchers have made significant strides in immunotherapy—such as PD-1/PD-L1 inhibitors—and have advanced new targeted therapies, including CDK4/6 inhibitors and PARP inhibitors.
Despite the challenges in breast cancer drug development, the outlook remains promising. Advances in biomarkers and genome sequencing enhance diagnostic accuracy and targeted therapies. Nanotechnology and innovative delivery systems improve efficacy and reduce side effects. With multidisciplinary collaboration and ongoing innovation, we remain confident in overcoming obstacles.
| Immune Checkpoint Inhibitor | PD-1, PD-L1, CTLA-4 |
| Cancer Growth Inhibitor | CDK, VEGF–VEGFR, PI3K/AKT/mTOR Pathway, PARP |
| Cytokine and Chemokine Pathway Inhibitor | TNF-α, IL-1, IL-6, Chemokine receptors |
| Metabolic Inhibitor | Glutamine and Arginine, Adenosine, Kynurenine |
| Protein Kinase Inhibitor | EGFR, HER2, ALK |
| Cancer Stem Cells Inhibitor | CDK, Notch, Wnt |
| TAM Modulator | EGFR, AXL, MER, TYRO3 |
| NK Modulator | NKG2D, NKp30, NKp44, NKp46, NKG2A, KIR |
| lAP Inhibitor | XIAP, cIAP1, NF-κB |
| Autophagy Inhibitor | VPS34, ATG, mTOR, Beclin 1 |
Identify key cytokines and chemokines linked to cancer progression via research and bioinformatics.
Using HTS and virtual screening, we identify lead compounds that inhibit selected targets.
Using SBDD-guided iterations in medicinal chemistry, we improve lead compounds’ potency, selectivity, and pharmacokinetics.
Lead compounds undergo in vitro and in vivo studies to evaluate efficacy, safety, and mechanisms.
The synergy of cytokine and chemokine pathway inhibitors with chemotherapy, immunotherapy, and targeted therapy is assessed.
| Breast Cancer Animal Models | Applications in breast cancer include studying its occurrence and development in vivo. |
| 3D Tumor Model for Breast Cancer | Applications in breast cancer include screening of anti-tumor drug compounds and validation of treatment methods. |
| Breast Cancer Cell Models | Applications in breast cancer focus on drug testing for tumor prevention and treatment. |
Stay ahead in breast cancer research! Subscribe now for updates on breakthrough drug developments, innovative therapies, and cutting-edge prevention strategies.
Comprehensive services for developing small molecule drugs that offer targeted and efficient treatment options for breast cancer.
Cutting-edge solutions for creating therapeutic antibodies that specifically target breast cancer cells.
Advanced vaccine development services focused on creating therapeutic vaccines to stimulate the immune system to fight breast cancer.
Developing animal models to study the mechanisms and potential treatments of breast cancer.
Utilizing three-dimensional spheroid cultures to mimic the tumor microenvironment for breast cancer research.
Identifying specific biological markers for early detection, diagnosis, and treatment monitoring of breast cancer.
Conducting laboratory studies to evaluate the efficacy and safety of new breast cancer treatments before clinical trials.
Investigating the fundamental biological processes and genetic factors involved in the development and progression of breast cancer.
Leverage the experience of seasoned researchers with a deep understanding of cancer biology and metabolism.
Access the latest tools and methodologies for accurate and reliable data.
Tailor our services to meet your unique research needs and objectives.
Benefit from our commitment to efficiency and timely project completion.
Enjoy end-to-end support from experimental design to data analysis, ensuring research success.
The development involves using human breast cancer cell lines, which can be cultured in 2D monolayers or 3D spheroid models to closely mimic the tumor microenvironment for drug testing.
Targeted therapy involves drugs that specifically target cancer cell pathways, while chemotherapy uses drugs that kill rapidly dividing cells indiscriminately. Targeted therapy often has fewer side effects compared to chemotherapy.
Models include genetically engineered mouse models, patient-derived xenografts, and syngeneic mouse models, each serving different research needs in drug response and resistance.
Biomarkers help in identifying patients most likely to benefit from a drug, predicting response to treatment, and monitoring treatment effectiveness, aiding in personalized medicine approaches.
Challenges include overcoming drug resistance, ensuring effective drug delivery to the tumor site, minimizing side effects, and the high cost and time involved in clinical trials.
